CD38 and lymphoma: Studies have shown that patients with lymphoma are particularly vulnerable to SARS-CoV-2 infection, possibly due to the antineoplastic regimens such as BTL or PI3 kinase inhibitors, monocolonal antibodies for CD20, CD30, or CD38, and CAR-T therapy [18,19].